3651 results for «340»
3651 results
From crossroads to crossovers: cracking the left main code
20 May 2025 – From EuroPCR 2025
Navigate complex scenarios in left main coronary artery interventions with this session focusing on protected left main and multivessel disease, IVUS-guided PCI, stent optimization, and in-stent restenosis management. Real-world cases from Azerbaijan, Moldova, and Iraq provide collaborative insights and innovative strategies for challenging coronary anatomy.
Strategic decision in stent failure
20 May 2025 – From EuroPCR 2025
Explore strategic decision-making in cases of stent failure in this session presenting complex clinical scenarios. Through detailed case analyses, including challenging left main trifurcation lesions and NSTEMI in the presence of chronic total occlusions, discover treatment approaches and key learnings to optimize patient outcomes.
STEMI - What if a culprit lesion is not identifiable?
20 May 2025 – From EuroPCR 2025
Address challenging STEMI cases where culprit lesions are not immediately identifiable. This session emphasizes the utility of intravascular imaging in guiding decision-making and optimizing percutaneous interventions through illustrative cases involving left main stenosis, ambiguous culprit lesions, and etiological dilemmas in coronary occlusion.
Integrative step-by-step approach to perform successful CTO interventions: from angiographic evaluation to strategy selection
20 May 2025 – From EuroPCR 2025
Master the integrative step-by-step approach to successful chronic total occlusion (CTO) interventions. This session emphasizes systematic angiographic evaluation and strategy selection ranging from simple to complex techniques, supplemented by blinded case discussions for practical learning.
Managing TAVI complications
20 May 2025 – From EuroPCR 2025
Gain expertise in managing TAVI complications including strategic retrieval of embolized valves, handling unexpected additional valve usage, managing left ventricle suicide phenomenon, and integrating coronary intervention tools during structural heart procedures, supported by instructive case series.
Novelty in no-reflow management in STEMI patients
20 May 2025 – From EuroPCR 2025
Discover novel approaches to manage no-reflow phenomenon in STEMI patients. This session covers innovative therapies including the OPTI-STEMI trial strategies, mechanical thrombectomy, pharmacological interventions with Cangrelor, and super saturated oxygen therapy targeting coronary microcirculation preservation.
PCI in cardiogenic shock without left ventricular support
20 May 2025 – From EuroPCR 2025
Explore PCI strategies in cardiogenic shock without left ventricular support through challenging cases including STEMI with single patent vessels, balancing procedural and resource considerations, spontaneous coronary dissections with arrhythmia, and use of crush techniques to rescue critically ill patients.
Contemporary challenges in acute coronary syndromes
20 May 2025 – From EuroPCR 2025
Examine contemporary challenges in acute coronary syndromes (ACS) through recent trials and studies. Topics include long-term outcomes of deferred stenting, thrombectomy techniques, PCI in cardiogenic shock, and revascularisation strategies, providing a comprehensive update for clinical practice.
Primary left ventricular unloading in anterior STEMI without cardiogenic shock: Results from the STEMI-Door to Unload randomized clinical trial
28 Mar 2026
Elad Asher provides his take on the STEMI-DTU trial, which was presented by Navin K. Kapur at the ACC.26 in New Orleans, and simultaneously published in the JACC.
Author
Mid-term echocardiographic outcomes following transapical mitral valve replacement: Updates from the Intrepid Pilot Study
19 Sep 2022
Pamela Gatto provides her take on the Intrepid Global Pilot Study which was presented by Renuka Jain at TCT Congress 2022.
Author
3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications
22 Mar 2022
Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.
Author
